Minwei Biotechnology

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Minwei Biotechnology details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Minwei Biotechnology please access flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Minwei Biotechnology details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Minwei Biotechnology please access flcube.com

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
CompanyDrug

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Alphamab Oncology (HKG: 9966) announced that the first patient has been successfully dosed in the Phase III clinical study of JSKN033 monotherapy for recurrent or metastatic cervical cancer – irrespective…

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Lepu Medical Subsidiary Secures FDA IND Clearance for MWN117 siRNA Targeting INHBE – Novel Obesity Drug Shows Synergy With GLP‑1 and Muscle Preservation in Primate Studies
CompanyDrug

Lepu Medical Subsidiary Secures FDA IND Clearance for MWN117 siRNA Targeting INHBE – Novel Obesity Drug Shows Synergy With GLP‑1 and Muscle Preservation in Primate Studies

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
CompanyDeals

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment